Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Mallinckrodt
Johnson and Johnson
Merck
Harvard Business School

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Alemtuzumab - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for alemtuzumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Northwestern UniversityPhase 2
M.D. Anderson Cancer CenterPhase 1
Isaac Tunez-FiƱanaPhase 1/Phase 2

See all alemtuzumab clinical trials

Recent Litigation for alemtuzumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
CELGENE CORPORATION v. SANDOZ INC.2018-06-26

See all alemtuzumab litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Forty Seven, Inc.2016-08-08
Forty Seven, Inc.2016-08-05

See all alemtuzumab litigation

Pharmacology for alemtuzumab

Company Disclosures: US Patents for alemtuzumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2014-08-05 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial British Technology Group Limited (London, GB) 2015-12-08 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial BTG International Limited (London, GB) 2020-05-27 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for alemtuzumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for alemtuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90025-0 Sweden   Start Trial PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916
0968 Netherlands   Start Trial PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: EU/1/18/1297 19760826
2016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
0822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2016 00026 Denmark   Start Trial PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916
2018502,C1608344 Lithuania   Start Trial PRODUCT NAME: KLADRIBINAS; REGISTRATION NO/DATE: EU1/17/1212/001-006 20170822
2016000041 Germany   Start Trial PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130912
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Merck
Moodys
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.